Almost a year after being initially approved by the US Food and Drug Administration, Eli Lilly’s Rezvoglar (insulin glargine-aglr) biosimilar has been granted an interchangeability designation by the regulator, making it the second approved interchangeable insulin product in the US.
Lilly Gets Second Interchangeable Insulin Glargine In US
Further FDA Approval For Rezvoglar Biosimilar Adds Second Interchangeable Option
Eli Lilly has been granted an interchangeability designation by the US FDA for its Rezvoglar insulin glargine biosimilar, matching the designation previously granted for Viatris’ Semglee.
